GO-Y078
GO-Y078 is a curcumin (HY-N0005) analog. GO-Y078 activates p38/JNK1/2. GO-Y078 activates the MAPK pathway, Caspase 3/8/9, PARP, AP-1, DR5, and TP53, while inhibiting cIAP-1, XIAP, and NF-κB. GO-Y078 induces sub-G1/G2/M phase arrest and Apoptosis. GO-Y078 impairs angiogenesis. GO-Y078 can be used in research related to osteosarcoma, cervical cancer, oral squamous cell carcinoma, and peritoneal metastasis of gastric cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 1217503-60-0
- 分子式: C22H24O7
- 分子量:400.43
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
[1]|
cIAP-1 |
XIAP |
Caspase 3 |
Caspase 8 |
Caspase 9 |
JNK1 |
JNK2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SiHa | IC50 |
7.76 μM
|
Inhibition of cell viability against human cervical squamous cell carcinoma SiHa cells assessed via MTT-based colorimetric assay after 24 h incubation.
Inhibition of cell viability against human cervical squamous cell carcinoma SiHa cells assessed via MTT-based colorimetric assay after 24 h incubation.
|
42059340 |
| HeLa | IC50 |
11.94 μM
|
Inhibition of cell viability against human cervical adenocarcinoma HeLa cells assessed via MTT-based colorimetric assay after 24 h incubation.
Inhibition of cell viability against human cervical adenocarcinoma HeLa cells assessed via MTT-based colorimetric assay after 24 h incubation.
|
42059340 |
体外実験
GO-Y078 (1-16 μM; 24 h) reduces the viability of osteosarcoma U2OS, MG-63, 143B and Saos-2 cells in a dose-dependent manner. After 24 h of treatment, the inhibitory effect is the strongest at the concentration of 16 μM (the viability of U2OS cells decreases by 54.7%, that of MG-63 cells by 79.6%, that of 143B cells by 58.9%, and that of Saos-2 cells by 71.6%)[1].
GO-Y078 (2.5-40 μM; 24 h) inhibits the viability of cervical squamous cell carcinoma SiHa cells and cervical adenocarcinoma HeLa cells, with an IC50 of 7.76 μM for the former and 11.94 μM for the latter[2].
GO-Y078 (0.5-4 μM; 24 h) potently inhibits the viability of SCC-9 and HSC-3 oral squamous cell carcinoma cells, with an IC50 of <4 μM, and exhibits stronger cytotoxic potency than DMC[3].
GO-Y078 (1-8 μM; 24 h) induces sub-G1 phase cell cycle arrest in osteosarcoma U2OS and 143B cells. After treatment with 8 μM for 24 h, the proportion of sub-G1 phase cells increases to 24.3% in U2OS cells and to 26.9% in 143B cells[1].
GO-Y078 (1-8 μM; 24 h) induces apoptosis in osteosarcoma U2OS and 143B cells in a dose-dependent manner. After 24 h of treatment, the proportion of Annexin V-positive cells increases to approximately 35% in U2OS cells and to approximately 50% in 143B cells at the concentration of 8 μM[1].
GO-Y078 (1-8 μM; 24 h) reduces the expression of anti-apoptotic proteins cIAP-1 and XIAP in osteosarcoma U2OS and 143B cells in a dose-dependent manner, while upregulating the level of pro-apoptotic activated caspase-3 in U2OS cells after 24 h of treatment[1].
GO-Y078 (1-8 μM; 24 h) activates the ERK1/2, JNK1/2 and p38 MAPK signaling pathways in osteosarcoma U2OS and 143B cells in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human osteosarcoma U2OS, MG-63, 143B, and Saos-2 cells
-
Concentration:1-16 μM
-
Incubation Time:24 h
-
Result:Reduced cell viability in a dose-dependent manner across all four cell lines.
Reduced U2OS cell viability by 41.5% at 8 μM and 54.7% at 16 μM.
Reduced MG-63 cell viability by 39.9% at 8 μM and 79.6% at 16 μM.
Reduced 143B cell viability by 51.8% at 8 μM and 58.9% at 16 μM.
Reduced Saos-2 cell viability by 57.4% at 8 μM and 71.6% at 16 μM.
-
Cell Line:human osteosarcoma U2OS and 143B cells
-
Concentration:1-8 μM
-
Incubation Time:24 h
-
Result:Caused a dose-dependent increase in the sub-G1 cell fraction in both cell lines.
Increased U2OS sub-G1 fraction from 4.7% (control) to 24.3% at 8 μM.
Increased 143B sub-G1 fraction from 5.2% (control) to 26.9% at 8 μM.
-
Cell Line:human osteosarcoma U2OS and 143B cells
-
Concentration:1-8 μM
-
Incubation Time:24 h
-
Result:Caused a dose-dependent increase in total Annexin V-positive (early + late apoptotic) cells in both cell lines.
Increased U2OS Annexin V-positive cells to ~35% at 8 μM.
Increased 143B Annexin V-positive cells to ~50% at 8 μM.
-
Cell Line:human osteosarcoma U2OS and 143B cells
-
Concentration:8 μM (apoptosis array); 1-8 μM (Western blot)
-
Incubation Time:24 h (apoptosis array); 24 h (Western blot)
-
Result:Increased cleaved caspase-3 levels and decreased cIAP-1 and XIAP levels in U2OS cells at 8 μM (apoptosis array).
Caused dose-dependent reductions in cIAP-1 and XIAP expression in both U2OS and 143B cells.
Reduced U2OS cIAP-1 to near 0% and XIAP to near 10% of control levels at 8 μM.
Reduced 143B cIAP-1 to ~20% and XIAP to ~40% of control levels at 8 μM.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:KSN/Slc (nu/nu) (6-week-old male, peritoneal carcinomatosis model established by intraperitoneal inoculation of GCIY gastric cancer cells)[5]
-
Dosage:133 mg/kg; 266 mg/kg
-
Administration:i.p.
-
Result:Suppressed ascites fluid accumulation completely, with average body weight of 29.1 g at 17 days after first treatment.
Increased median survival time to 30.5 days, representing an approximate 40% increase in survival time.
Extended survival time range to 25 to 109 days.
化学情報
-
CAS 番号 1217503-60-0
-
分子量 400.43
-
分子式 C22H24O7
-
SMILES
O(C)C1=C(OC)C(OC)=CC(/C=C/C(/C=C/C2=CC(OC)=C(O)C(OC)=C2)=O)=C1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Keywords
- GO-Y078
- 1217503-60-0
- Drug Derivative
- p38 MAPK
- JNK
- Caspase
- PARP
- AP-1
- TNF Receptor
- MDM-2/p53
- IAP
- NF-κB
- Apoptosis
- MAPK pathway
- oral squamous cell carcinoma
- human osteosarcoma U2OS cells
- human cervical squamous cell carcinoma SiHa cells
- osteosarcoma
- p38
- cell cycle arrest
- JNK1/2
- apoptosis
- cervical cancer
- Inhibitor
- inhibitor
- inhibit